A detailed history of Vanguard Group Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 9,225,981 shares of ITCI stock, worth $668 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,225,981
Previous 9,094,302 1.45%
Holding current value
$668 Million
Previous $651 Million 1.98%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$64.37 - $75.65 $8.48 Million - $9.96 Million
131,679 Added 1.45%
9,225,981 $638 Million
Q4 2023

Feb 14, 2024

BUY
$46.37 - $73.65 $25.7 Million - $40.8 Million
554,577 Added 6.49%
9,094,302 $651 Million
Q3 2023

Nov 14, 2023

BUY
$52.09 - $64.1 $2.28 Million - $2.8 Million
43,689 Added 0.51%
8,539,725 $445 Million
Q2 2023

Aug 14, 2023

BUY
$54.67 - $66.44 $2.89 Million - $3.51 Million
52,879 Added 0.63%
8,496,036 $538 Million
Q1 2023

May 15, 2023

BUY
$43.8 - $56.99 $5.43 Million - $7.06 Million
123,908 Added 1.49%
8,443,157 $457 Million
Q4 2022

Feb 10, 2023

BUY
$44.07 - $54.45 $8.96 Million - $11.1 Million
203,229 Added 2.5%
8,319,249 $440 Million
Q3 2022

Nov 14, 2022

BUY
$42.7 - $59.99 $1.53 Million - $2.15 Million
35,822 Added 0.44%
8,116,020 $378 Million
Q2 2022

Aug 12, 2022

BUY
$43.0 - $65.64 $12.5 Million - $19.1 Million
291,729 Added 3.75%
8,080,198 $461 Million
Q1 2022

May 13, 2022

BUY
$38.74 - $62.09 $35.3 Million - $56.6 Million
912,268 Added 13.27%
7,788,469 $477 Million
Q4 2021

Feb 14, 2022

SELL
$35.2 - $53.42 $540,953 - $820,958
-15,368 Reduced 0.22%
6,876,201 $360 Million
Q3 2021

Nov 12, 2021

BUY
$28.72 - $42.49 $1.81 Million - $2.68 Million
63,132 Added 0.92%
6,891,569 $257 Million
Q2 2021

Aug 13, 2021

BUY
$29.3 - $44.5 $200 Million - $304 Million
6,828,437 New
6,828,437 $279 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $6.84B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.